296 related articles for article (PubMed ID: 15797972)
1. Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis.
Hayakawa I; Hasegawa M; Matsushita T; Yanaba K; Kodera M; Komura K; Takehara K; Sato S
Rheumatology (Oxford); 2005 Jul; 44(7):873-8. PubMed ID: 15797972
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of a Th1 chemoattractant IP-10 and Th2 chemoattractants, TARC and MDC, are elevated in patients with systemic sclerosis.
Fujii H; Shimada Y; Hasegawa M; Takehara K; Sato S
J Dermatol Sci; 2004 Jun; 35(1):43-51. PubMed ID: 15194146
[TBL] [Abstract][Full Text] [Related]
3. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of the CXC chemokines interleukin 8 and growth-regulated oncogene-alpha are elevated in patients with systemic sclerosis.
Furuse S; Fujii H; Kaburagi Y; Fujimoto M; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2003 Jul; 30(7):1524-8. PubMed ID: 12858452
[TBL] [Abstract][Full Text] [Related]
5. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes.
Matsushita T; Hasegawa M; Yanaba K; Kodera M; Takehara K; Sato S
Arthritis Rheum; 2006 Jan; 54(1):192-201. PubMed ID: 16385515
[TBL] [Abstract][Full Text] [Related]
6. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations.
Kodera M; Hayakawa I; Komura K; Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2005 Apr; 32(4):629-36. PubMed ID: 15801017
[TBL] [Abstract][Full Text] [Related]
7. Serum CXCL16 concentrations correlate with the extent of skin sclerosis in patients with systemic sclerosis.
Yanaba K; Muroi E; Yoshizaki A; Hara T; Ogawa F; Shimizu K; Yozaki M; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 Sep; 36(9):1917-23. PubMed ID: 19605674
[TBL] [Abstract][Full Text] [Related]
8. Serum CCL23 levels are increased in patients with systemic sclerosis.
Yanaba K; Yoshizaki A; Muroi E; Ogawa F; Asano Y; Kadono T; Sato S
Arch Dermatol Res; 2011 Jan; 303(1):29-34. PubMed ID: 20824279
[TBL] [Abstract][Full Text] [Related]
9. Elevated circulating CD40L concentrations in patients with systemic sclerosis.
Komura K; Sato S; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2004 Mar; 31(3):514-9. PubMed ID: 14994397
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis.
Matsushita T; Hasegawa M; Hamaguchi Y; Takehara K; Sato S
J Rheumatol; 2006 Feb; 33(2):275-84. PubMed ID: 16465658
[TBL] [Abstract][Full Text] [Related]
12. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis.
Hara T; Ogawa F; Muroi E; Komura K; Takenaka M; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 Mar; 35(3):451-7. PubMed ID: 18203319
[TBL] [Abstract][Full Text] [Related]
13. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell- attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis.
Hijnen D; De Bruin-Weller M; Oosting B; Lebre C; De Jong E; Bruijnzeel-Koomen C; Knol E
J Allergy Clin Immunol; 2004 Feb; 113(2):334-40. PubMed ID: 14767451
[TBL] [Abstract][Full Text] [Related]
14. Increased serum pentraxin 3 in patients with systemic sclerosis.
Iwata Y; Yoshizaki A; Ogawa F; Komura K; Hara T; Muroi E; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Takehara K; Sato S
J Rheumatol; 2009 May; 36(5):976-83. PubMed ID: 19273457
[TBL] [Abstract][Full Text] [Related]
15. Elevation of serum lymphotactin levels in patients with systemic sclerosis.
Muroi E; Ogawa F; Shimizu K; Komura K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2008 May; 35(5):834-8. PubMed ID: 18322986
[TBL] [Abstract][Full Text] [Related]
16. Serum levels of cutaneous T-cell attracting chemokine (CTACK) as a laboratory marker of the severity of atopic dermatitis in children.
Hon KL; Leung TF; Ma KC; Li AM; Wong Y; Fok TF
Clin Exp Dermatol; 2004 May; 29(3):293-6. PubMed ID: 15115514
[TBL] [Abstract][Full Text] [Related]
17. Increased serum thymus and activation-regulated chemokine and cutaneous T cell-attracting chemokine levels in children with atopic dermatitis.
Song TW; Sohn MH; Kim ES; Kim KW; Kim KE
Clin Exp Allergy; 2006 Mar; 36(3):346-51. PubMed ID: 16499646
[TBL] [Abstract][Full Text] [Related]
18. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
[TBL] [Abstract][Full Text] [Related]
19. Elevated serum insulin-like growth factor (IGF-1) and IGF binding protein-3 levels in patients with systemic sclerosis: possible role in development of fibrosis.
Hamaguchi Y; Fujimoto M; Matsushita T; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2008 Dec; 35(12):2363-71. PubMed ID: 19004037
[TBL] [Abstract][Full Text] [Related]
20. Anti-agalactosyl IgG antibodies in sera from patients with systemic sclerosis.
Nishijima C; Sato S; Takehara K
J Rheumatol; 2001 Aug; 28(8):1847-51. PubMed ID: 11508588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
